Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2011-10-12
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 296
- Registration Number
- NCT01450696
An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2016-07-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 74
- Registration Number
- NCT01442155
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
- Conditions
- Estrogen Receptor Positive TumorBreast Cancer
- Interventions
- First Posted Date
- 2011-09-23
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT01439282
- Locations
- 🇺🇸
New York Oncology Hematology, P.C., Albany, New York, United States
🇺🇸Arizona Oncology Associates, PC - CASA, Tucson, Arizona, United States
🇺🇸Sciode Medical Associates, PLLC, d.b.a. Eastchester Center, Bronx, New York, United States
Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2011-09-14
- Last Posted Date
- 2015-09-17
- Lead Sponsor
- Thomas Hatschek
- Target Recruit Count
- 304
- Registration Number
- NCT01433614
- Locations
- 🇸🇪
Sahlgrenska University Hospital, Göteborg, Sweden
🇸🇪Kalmar Central Hospital, Kalmar, Sweden
🇸🇪Helsingborg Gen. Hospital, Helsingborg, Sweden
Study of Ruxolitinib in Pancreatic Cancer Patients
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2011-08-26
- Last Posted Date
- 2018-02-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 136
- Registration Number
- NCT01423604
Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer
- Conditions
- Esophageal CancerMalignant Neoplasm of Cardio-esophageal Junction of Stomach
- Interventions
- First Posted Date
- 2011-07-01
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 12
- Registration Number
- NCT01386346
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2011-06-16
- Last Posted Date
- 2016-08-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 376
- Registration Number
- NCT01374425
Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- David A. Clump, MD, PhD
- Target Recruit Count
- 35
- Registration Number
- NCT01360593
- Locations
- 🇺🇸
UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States
E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer
- Conditions
- Advanced or Metastatic Solid TumorsPreviously Untreated Gastric Cancer
- Interventions
- First Posted Date
- 2011-05-18
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT01355302
- Locations
- 🇺🇸
Boca Raton Clinical Research Associates, Inc, Plantation, Florida, United States
🇺🇸Robert H. Lurie Comprenhensive Cancer Center of Northwestern University, Chicago, Illinois, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer
- Conditions
- Metastatic Breast CancerStage IV Breast CancerBreast Cancer
- Interventions
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.